Quick Answer
Sunshine Biopharma Inc. reported R&D Expense of $933.9 thousand for fiscal year 2024.
Sunshine Biopharma Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $933.9K | -49.7% |
| 2023 | $1.86M | +128.6% |
| 2022 | $811.9K | +20.8% |
| 2021 | $672.2K | +38801.0% |
| 2020 | $1.7K | -88.6% |
| 2019 | $15.2K | +18.8% |
| 2018 | $12.8K | — |
| 2017 | $0.00 | -100.0% |
| 2016 | $32.8K | +278.8% |
| 2015 | $8.7K | -97.4% |
| 2014 | $327.0K | +138.0% |
| 2013 | $137.4K | +7412.3% |
| 2012 | $1.8K | -98.7% |
| 2011 | $142.7K | — |
| 2010 | $0.00 | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $119.3K | -5.6% | -39.2% |
| June 30, 2025 | $196.2K | -55.0% | -8.8% |
| March 31, 2025 | $215.3K | -3.0% | +70.4% |
| September 30, 2024 | $126.4K | -46.9% | -71.0% |
| June 30, 2024 | $436.2K | +18.4% | +96.5% |
| March 31, 2024 | $222.0K | -48.7% | -6.7% |
| September 30, 2023 | $238.0K | -34.3% | -35.4% |
| June 30, 2023 | $368.6K | +702.2% | -14.9% |
- Sunshine Biopharma Inc. showed a decrease of -49.7% in R&D Expense compared to the prior fiscal year.
- The most recent figure is from Sunshine Biopharma Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 1, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: